Business Trends– category –
-
Vertex Pharmaceuticals Secures FDA IND Approval for iPSC-Derived Type 1 Diabetes Therapies, Boosts 2026 Revenue Forecast
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced robust Q2 2026 financial results and significantly raised its full-year revenue guidance, propelled by key pipeline advancements. The company secured FDA Investigationa... -
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
Allogeneic CAR T-Cells: The Off-the-Shelf Revolution in Cancer Immunotherapy Manufacturing
Liv Hospital Turkey Overview Autologous CAR T-cell therapies face significant hurdles in scalability and turnaround time, limiting their broad accessibility. The industry is rapidly shifting towards off-the-shelf allogeneic CAR T-cells, ... -
Intellia Therapeutics Reports Positive Phase 3 HAELO Data for lonvo-z in HAE and Resumes Nex-z ATTR Phase 3 Enrollment
Intellia Therapeutics USA Overview Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), published in the New England Journal of Medicine. The company anticipates FDA Biologics L... -
Pharmaceuticals and Medical Devices Agency (PMDA) Updates Regenerative Medicine Product Approval List and Advances International Regulatory Harmonization
Pharmaceuticals and Medical Devices Agency (PMDA) Japan Overview On August 5, 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) updated its approval list for regenerative medicine products, covering April 2015 to May 2026. ... -
Editas Medicine’s CRISPR Candidate EDIT-401 Achieves Over 90% Reduction in LDL Cholesterol in Non-Human Primates, Suggesting Long-Term Durability for Dyslipidemia
Editas Medicine USA Overview Editas Medicine announced updated preclinical data for EDIT-401, a CRISPR-based investigational drug for dyslipidemia, showing highly promising results. A single dose of EDIT-401 in non-human primate models a... -
FDA Regenerative Medicine Approvals Accelerate, Outpacing Previous Years with Record Potential for 2026
PharmaLive USA Overview FDA approvals for regenerative medicine products are accelerating significantly, with a record eight approvals in 2024. Approvals between 2023 and 2025 more than doubled the total from 2016-2022. As of July 2026, ... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Washington University Reports Promising Early Results for Aggressive Blood Cancers with Combined CRISPR Gene Editing and Stem Cell Transplant
The Brighter Side of News USA Overview Researchers at Washington University School of Medicine in St. Louis reported promising early results from a clinical trial combining CRISPR gene editing with stem cell transplantation to treat aggr... -
NueCell Bio Launches as Translational Partner to Accelerate Cell Therapies from Discovery to GMP Manufacturing
PR Newswire USA Overview NueCell Bio has officially launched as a new "translational partner" dedicated to accelerating cell therapy products from scientific discovery through GMP-compliant manufacturing and clinical readiness. The compa...
